• Revenue grew 63% to $15.9m
• Underlying loss reduced 28% to $12.7m
• Secured first US commercial contract, unlocking a major market

Genetic Signatures [ASX:GSS] ('GSS' or 'the Company), a global molecular diagnostics company, announced its results for the year ended 30 June 2025 (FY25). Revenue grew 63% to $15.9m, driven by strong respiratory sales in the Australian market. The company's underlying loss reduced 28% to $12.7m, reflecting the positive impact of increased revenue, management's focus on core business operations, and disciplined cost management. The company reported a statutory loss of $20.1m for FY25, which includes a one-off impairment expense of $7.0m. During the year, GSS executed a series of strategic and operational initiatives to sharpen its focus on core business pillars, streamline its product portfolio, and reshape its organizational structure. The company also discontinued the development of its proposed Next Generation instrument and instead partnered with Tecan Group and Repado Ltd to adapt a proven liquid handling platform and develop customized control software and a next-generation results analysis system. In FY25, GSS achieved a key milestone with the signing of its first US commercial agreement for the EasyScreen™ Gastrointestinal Parasite Detection Kit, which gained FDA clearance in June 2024. The company also saw positive momentum in the UK, where multiple NHS Hospital Trusts adopted its enteric viral, bacterial, and parasite test kits. At the end of FY25, GSS held $30.9m in cash and equivalents, providing a strong foundation for future growth.

The company reported revenue of $15.9m and an underlying loss of $12.7m for FY25. No other high-importance, price-sensitive forward-looking financial metrics were provided.